A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia (Q34660425)

3 August 2017

title

A controlled, evidence-based trial of paliperidone palmitate, a long-acting injectable antipsychotic, in schizophrenia (English)

1 reference

3 August 2017

0 references

1

Henry A Nasrallah

1 reference

3 August 2017

Srihari Gopal

2

1 reference

3 August 2017

Cristiana Gassmann-Mayer

3

1 reference

3 August 2017

Jorge A Quiroz

4

1 reference

3 August 2017

Pilar Lim

5

1 reference

3 August 2017

Mariëlle Eerdekens

6

1 reference

3 August 2017

Eric Yuen

7

1 reference

3 August 2017

David Hough

8

1 reference

3 August 2017

language of work or name

English

0 references

publication date

16 June 2010

1 reference

3 August 2017

published in

Neuropsychopharmacology

1 reference

3 August 2017

volume

35

1 reference

3 August 2017

issue

10

1 reference

3 August 2017

page(s)

2072-2082

1 reference

Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study

3 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055301

The case for long-acting antipsychotic agents in the post-CATIE era.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055301

Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic

7 July 2018

2 references

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055301

7 July 2018

https://api.crossref.org/works/10.1038%2FNPP.2010.79

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055301

A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055301

Partial compliance and patient consequences in schizophrenia: our patients can do better.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055301

The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055301

Antipsychotics and QT prolongation

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055301

Strategies for increasing treatment compliance: the role of long-acting antipsychotics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055301

Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055301

A rating scale for extrapyramidal side effects

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055301

A rating scale for drug-induced akathisia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055301

Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia.

7 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.79

Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.79

Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.79

Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.79

A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.79

Switching to long-acting injectable risperidone is beneficial with regard to clinical outcomes, regardless of previous conventional medication in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.79

Reliability, validity and ability to detect change of the Personal and Social Performance scale in patients with stable schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.79

Safety and tolerability: how do newer generation "atypical" antipsychotics compare?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2010.79

Efficacy and safety of paliperidone palmitate in adult patients with acutely symptomatic schizophrenia: a randomized, double-blind, placebo-controlled, dose-response study

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055301

Early clinical experience with risperidone long-acting injection: a prospective, 6-month follow-up of 100 patients

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055301

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055301

Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3055301

Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics

26 October 2018

1 reference

12 December 2020

Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study

1 reference

12 December 2020

Adherence to atypical antipsychotic treatment among newly treated patients: a population-based study in schizophrenia

1 reference

12 December 2020

Reliability, validity and ability to detect change of the clinician-rated Personal and Social Performance scale in patients with acute symptoms of schizophrenia

1 reference

12 December 2020

Identifiers

DOI

10.1038/NPP.2010.79

1 reference

Dimensions Publication ID

3 August 2017

0 references

1 reference

3 August 2017

1 reference